{"url_path":"/sec/cingw/8-k/2026-06-02/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/1862150/0001493152-26-026760-index.html","accession_number":"0001493152-26-026760","cik":"0001862150","ticker":"CING","issuer_name":"Cingulate Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1862150/0001493152-26-026760-index.html","primary_entity_key":"0001862150","primary_entity_name":"Cingulate Inc."},"word_count":72,"has_tables":true,"body_markdown":"**Item\n8.01 Other Events.**\n\n \n\nOn\nJune 2, 2026, the Company announced that the FDA has issued a CRL for its New Drug Application for CTx-1301. The\nFDA identified specific Chemistry, Manufacturing and Controls information requests in the CRL and did not raise any current\nconcerns regarding the clinical safety or efficacy of CTx-1301. The Company expects a prompt resubmission to FDA of the\nremaining requested information addressing issues raised in the CRL."}